Experimental treatment significantly slows progression of a fatal brain disease in women during clinical trial

MedicalXpress | 八月 02, 2026

Researchers at Tel Aviv University have presented new findings indicating that the experimental drug Davunetide may significantly slow the progression of progressive supranuclear palsy (PSP) in women, who exhibited a markedly different response to treatment than men. These results reinforce the need for sex-specific medicine in neurodegenerative diseases.